Detalles de la búsqueda
1.
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study.
RMD Open
; 10(1)2024 Feb 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38428974
2.
Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA).
RMD Open
; 9(1)2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36921980
3.
Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France.
RMD Open
; 8(1)2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35301266
4.
Personalised medicine in asthma: from curative to preventive medicine.
Eur Respir Rev
; 26(143)2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28049124
5.
Impact of Axial Spondyloarthritis on Quality of Life: Results From the European Map of Axial Spondyloarthritis (EMAS) Study in France.
J Rheumatol
; 49(10): 1176-1178, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35569828
Resultados
1 -
5
de 5
1
Próxima >
>>